TSC2 and cancer: SGK1, which is activated by 3-phosphoinositide dependent kinase-1 (PDK1), contributes to the maintenance of residual mTORC1 activity and cancer cell growth through direct phosphorylation and inhibition of tuberous sclerosis 2 (TSC2) (54).